| Could mobilized endothelial and their progenitor cell counts be used as biomarker for treatment efficacy and outcome in gastric cancer patients? |
|
, , , , , , , , , , , |
|
Laboratory of Endocrine Cell Biology, Department of Internal Medicine, School of Medicine, Chungnam National University, 640 Daesadong Chungku Daejeon 301-721 Korea. Division of Endocrinology1, Department of Internal Medicine, Eulji University Hospital,1 |
| Could mobilized endothelial and their progenitor cell counts be used as biomarker for treatment efficacy and outcome in gastric cancer patients? |
|
Sang Joon Shin, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Jong Keun Lim, Sung Ha Cheon, Hyun Chang, Jong Yul Jung, Hei-Cheul Jeung, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung |
|
. |
|
|
|
|
| Abstract |
Objective : We wanted to investigate whether the level of circulating endothelial progenitor cells (CEPCs) and endothelial cells
(CECs) could be used as a surrogate predictor of outcome in patients receiving chemotherapy for gastric cancer. Patients and
Methods : Circulating progenitor and endothelial cells were enumerated in 49 gastric cancer patients by means of flow
cytometry at the time of baseline, after the first, second cycle treatment of 5-FU, leucovorin and taxotere (FLT). To confirm
the endothelial phenotype, positive staining for specific endothelial cell marker [i.e. CD34, von Willebrand factor, P1H12, CD31]
was used. The changes of CEPCs and CECs and prognostic effect of them during treatment on progression and survival were
investigated. Results : The number of CD34+vWF+ and CD34+ cells were significantly higher in responder than non-responder
to chemotherapy (p=0.012 and p=0.008, respectively). In addition, the level of CD31+ cells determined after the second cycle
chemotherapy significantly decreased compared with the first cycle in the patients who showed response (p=0.026). In
non-responder, however, the level of CD34+ cells significantly increased before the second cycle chemotherapy (p=0.034). In
univariate analysis, the level of CD34+ cells significantly related to the median time to progression (TTP) (6.1 and 4 months in
CD34low and CD34high, respectively, p=0.046) but none of the covariates related to the median overall survival (OS). By
multivariate analysis using a Cox proportional-hazard model, however, the level of markers was not a significant independent
prognostic factor for TTP and OS. Conclusion : Serial monitoring of CEPCs and CECs in blood may serve as an early surrogate
marker of predicting tumor response to chemotherapy and outcome of patients receiving chemotherapy for gastric cancer. |
|